← SynDRA
KI-16425
SynDRA canonical compound SYN0051214 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | LPAR3 |
|---|
| Mechanism of action | Lysophosphatidic acid receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- Lysophosphatidic acid receptor antagonist
- GPR87 ANTAGONIST
- LPAR2 ANTAGONIST
- LPAR3 ANTAGONIST
Cross-references
Synonyms
- Ki16425
- RefChem:910799
- CHEBI:91192
- DTXCID50389594
- Ki 16425
- C23H23ClN2O5S
- MFCD06798341
- MLS006010196
- UNII-83W49JT69B
- GTPL2907
- orb1301066
- SCHEMBL3841276
- CHEBI:91194
- HMS3654H15
- HMS3884M09
- EX-A2249
- BDBM50170859
- s1315
- AKOS015842002
- CCG-269493
- CS-0510
- EX-5959
- SB19554
- NCGC00165816-01
- NCGC00165816-02
- NCGC00165816-10
- AC-35873
- AS-16643
- HY-13285
- SMR004701298
- DB-069222
- SW219841-1
- T6108
- C74828
- BRD-A25569250-001-01-7
- BRD-A25569250-001-03-3
- 3-[({4-[4-({[1-(2-chlorophenyl)ethoxy]carbonyl}amino)-3-methyl-1,2-oxazol-5-yl]phenyl}methyl)sulfanyl]propanoic acid
- 3-[[[4-[4-[[[1-(2-Chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazolyl]phenyl]methyl]thio]propanoic acid
Look up KI-16425 in the interactive SynDRA portal →